NASDAQ:TTOO - T2 Biosystems Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.10
  • Forecasted Upside: 547.06 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.17
▲ +0.01 (6.25%)

This chart shows the closing price for TTOO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New T2 Biosystems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TTOO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TTOO

Analyst Price Target is $1.10
▲ +547.06% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for T2 Biosystems in the last 3 months. The average price target is $1.10, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 547.06% upside from the last price of $0.17.

This chart shows the closing price for TTOO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in T2 Biosystems. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/18/2022Canaccord Genuity GroupLower Price TargetBuy ➝ Buy$3.00 ➝ $1.50High
2/18/2022Alliance Global PartnersUpgradeNeutral ➝ Buy$0.70Low
5/14/2021SVB LeerinkReiterated RatingBuy$3.00Medium
3/5/2021Alliance Global PartnersLower Price TargetNeutral$2.40 ➝ $1.65High
1/27/2021JonestradingReiterated RatingBuy$3.50High
1/27/2021Alliance Global PartnersDowngradeBuy ➝ Neutral$2.60 ➝ $2.40High
1/27/2021SVB LeerinkLower Price TargetOutperform$4.00 ➝ $3.00High
11/5/2020Alliance Global PartnersBoost Price TargetBuy$1.65 ➝ $2.60Medium
11/5/2020SVB LeerinkBoost Price TargetOutperform$3.00 ➝ $4.00High
10/7/2020BTIG ResearchInitiated CoverageBuy$2.50Low
8/12/2020SVB LeerinkBoost Price TargetOutperform$2.00 ➝ $3.00High
5/6/2020SVB LeerinkReiterated RatingOutperform$5.00 ➝ $2.00High
1/23/2020Alliance Global PartnersUpgradeNeutral ➝ BuyHigh
11/26/2019Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
11/21/2019HC WainwrightReiterated RatingHoldMedium
9/12/2019SVB LeerinkSet Price TargetBuy$5.00Low
9/12/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy$6.00High
9/11/2019Janney Montgomery ScottReiterated RatingFair Value ➝ Neutral$2.00High
8/7/2019HC WainwrightReiterated RatingHoldMedium
8/1/2019Alliance Global PartnersDowngradeBuy ➝ Neutral$5.00 ➝ $0.40High
7/31/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
7/31/2019Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
7/31/2019Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
6/7/2019HC WainwrightSet Price TargetBuy$10.00High
5/31/2019HC WainwrightSet Price TargetBuy$10.00Medium
5/24/2019Cantor FitzgeraldSet Price TargetBuy$10.00Low
5/20/2019HC WainwrightReiterated RatingBuy$11.00High
5/16/2019Alliance Global PartnersInitiated CoverageBuy$5.00High
5/3/2019Cantor FitzgeraldReiterated RatingBuy$10.00High
3/8/2019HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $11.00High
3/5/2019Cantor FitzgeraldSet Price TargetBuy$11.00High
11/30/2018The Goldman Sachs GroupSet Price TargetHold$5.00High
11/2/2018HC WainwrightSet Price TargetBuy$14.00High
11/2/2018Cantor FitzgeraldSet Price TargetBuy$11.00High
10/8/2018HC WainwrightReiterated RatingBuy$14.00High
9/26/2018Cantor FitzgeraldSet Price TargetBuy$11.00High
9/20/2018Cantor FitzgeraldInitiated CoverageBuy$11.00Low
8/3/2018HC WainwrightSet Price TargetBuy$14.00High
6/14/2018HC WainwrightReiterated RatingBuy$14.00Medium
6/1/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
5/30/2018HC WainwrightReiterated RatingBuy$8.50 ➝ $14.00High
5/9/2018HC WainwrightSet Price TargetBuy$9.00High
5/9/2018Janney Montgomery ScottUpgradeNeutral ➝ BuyHigh
3/29/2018HC WainwrightBoost Price TargetBuy ➝ Buy$8.00 ➝ $8.50Low
3/7/2018HC WainwrightSet Price TargetBuy$8.00Low
2/12/2018HC WainwrightSet Price TargetBuy$8.00Low
1/29/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$5.20High
1/25/2018HC WainwrightReiterated RatingBuy$8.00Medium
11/3/2017HC WainwrightReiterated RatingBuy$8.00N/A
10/18/2017HC WainwrightInitiated CoverageBuy ➝ Buy$8.00N/A
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
T2 Biosystems logo
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $0.17
Low: $0.17
High: $0.17

50 Day Range

MA: $0.23
Low: $0.15
High: $0.40

52 Week Range

Now: $0.17
Low: $0.15
High: $1.23

Volume

87,944 shs

Average Volume

1,844,849 shs

Market Capitalization

$29.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of T2 Biosystems?

The following sell-side analysts have issued reports on T2 Biosystems in the last twelve months: Alliance Global Partners, Canaccord Genuity Group Inc., and StockNews.com.
View the latest analyst ratings for TTOO.

What is the current price target for T2 Biosystems?

0 Wall Street analysts have set twelve-month price targets for T2 Biosystems in the last year. Their average twelve-month price target is $1.10, suggesting a possible upside of 547.1%.
View the latest price targets for TTOO.

What is the current consensus analyst rating for T2 Biosystems?

T2 Biosystems currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TTOO will outperform the market and that investors should add to their positions of T2 Biosystems.
View the latest ratings for TTOO.

How do I contact T2 Biosystems' investor relations team?

T2 Biosystems' physical mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider's listed phone number is (781) 761-4646 and its investor relations email address is [email protected] The official website for T2 Biosystems is www.t2biosystems.com. Learn More about contacing T2 Biosystems investor relations.